Clinical Trials Browser

Interventional × Leukemia, Prolymphocytic × tafasitamab × Clear all

NCT02005289 2025-12-15

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

Phase 2 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic